Journal Article
. 2014 Mar; 20(9):2424-32.
doi: 10.1158/1078-0432.CCR-13-2648.

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

Lidia Robert 1 Jennifer Tsoi  Xiaoyan Wang  Ryan Emerson  Blanca Homet  Thinle Chodon  Stephen Mok  Rong Rong Huang  Alistair J Cochran  Begoña Comin-Anduix  Richard C Koya  Thomas G Graeber  Harlan Robins  Antoni Ribas  
Affiliations
  • PMID: 24583799
  •     40 References
  •     168 citations

Abstract

Purpose: To evaluate the immunomodulatory effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade with tremelimumab in peripheral blood mononuclear cells (PBMC).

Experimental Design: We used next-generation sequencing to study the complementarity-determining region 3 (CDR3) from the rearranged T-cell receptor (TCR) variable beta (V-beta) in PBMCs of 21 patients, at baseline and 30 to 60 days after receiving tremelimumab.

Results: After receiving tremelimumab, there was a median of 30% increase in unique productive sequences of TCR V-beta CDR3 in 19 out of 21 patients, and a median decrease of 30% in only 2 out of 21 patients. These changes were significant for richness (P = 0.01) and for Shannon index diversity (P = 0.04). In comparison, serially collected PBMCs from four healthy donors did not show a significant change in TCR V-beta CDR3 diversity over 1 year. There was a significant difference in the total unique productive TCR V-beta CDR3 sequences between patients experiencing toxicity with tremelimumab compared with patients without toxicity (P = 0.05). No relevant differences were noted between clinical responders and nonresponders.

Conclusions: CTLA4 blockade with tremelimumab diversifies the peripheral T-cell pool, representing a pharmacodynamic effect of how this class of antibodies modulates the human immune system.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang, Jason Jalil, +10 authors, Antoni Ribas.
Clin Cancer Res, 2011 May 12; 17(12). PMID: 21558401    Free PMC article.
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Antoni Ribas, Begoña Comin-Anduix, +15 authors, Jesus Gomez-Navarro.
Clin Cancer Res, 2009 Oct 01; 15(19). PMID: 19789309    Free PMC article.
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Antoni Ribas, Begoña Comin-Anduix, +9 authors, Alistair J Cochran.
Clin Cancer Res, 2009 Jan 02; 15(1). PMID: 19118070
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Lisa H Butterfield, Begonya Comin-Anduix, +10 authors, Antoni Ribas.
J Immunother, 2008 Mar 05; 31(3). PMID: 18317358    Free PMC article.
Species-diversity and pattern-diversity in the study of ecological succession.
E C Pielou.
J Theor Biol, 1966 Feb 01; 10(2). PMID: 5964400
Highly Cited.
A primer in longitudinal data analysis.
Garrett M Fitzmaurice, Caitlin Ravichandran.
Circulation, 2008 Nov 05; 118(19). PMID: 18981315
Review.
Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Sofie Wilgenhof, Stephanie Du Four, +5 authors, Bart Neyns.
J Immunother, 2013 Mar 19; 36(3). PMID: 23502769
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Oliver Klein, Lisa M Ebert, +11 authors, Jonathan Cebon.
Clin Cancer Res, 2009 Mar 26; 15(7). PMID: 19318477
Profiling critical cancer gene mutations in clinical tumor samples.
Laura E MacConaill, Catarina D Campbell, +28 authors, Levi A Garraway.
PLoS One, 2009 Nov 20; 4(11). PMID: 19924296    Free PMC article.
Highly Cited.
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.
Begoña Comin-Anduix, Hooman Sazegar, +9 authors, Antoni Ribas.
PLoS One, 2010 Sep 22; 5(9). PMID: 20856802    Free PMC article.
Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Sofie Wilgenhof, Stephanie Du Four, Hendrik Everaert, Bart Neyns.
Cancer Invest, 2012 Oct 10; 30(10). PMID: 23043499    Free PMC article.
Is tremelimumab beneficial in advanced melanoma?
Kenneth S Wilson, Rami Kotb.
J Clin Oncol, 2013 Jun 12; 31(22). PMID: 23752103
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Luis H Camacho, Scott Antonia, +8 authors, Antoni Ribas.
J Clin Oncol, 2009 Jan 14; 27(7). PMID: 19139427
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.
Harlan S Robins, Paulo V Campregher, +6 authors, Christopher S Carlson.
Blood, 2009 Aug 27; 114(19). PMID: 19706884    Free PMC article.
Highly Cited.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
Joseph A Blansfield, Kimberly E Beck, +9 authors, Richard M Sherry.
J Immunother, 2005 Oct 15; 28(6). PMID: 16224277    Free PMC article.
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S J O'Day, M Maio, +13 authors, J D Wolchok.
Ann Oncol, 2010 Feb 12; 21(8). PMID: 20147741
Highly Cited.
Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures.
Seema B Plaisier, Richard Taschereau, Justin A Wong, Thomas G Graeber.
Nucleic Acids Res, 2010 Jul 28; 38(17). PMID: 20660011    Free PMC article.
Highly Cited.
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
Antoni Ribas, John A Glaspy, +11 authors, Lisa H Butterfield.
J Immunother, 2004 Aug 18; 27(5). PMID: 15314544
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
F Stephen Hodi, Darryl A Oble, +8 authors, Martin Mihm.
Nat Clin Pract Oncol, 2008 Jul 31; 5(9). PMID: 18665147
Reply to K.S. Wilson et al.
Antoni Ribas, Axel Hauschild, Richard Kefford.
J Clin Oncol, 2013 Sep 24; 31(22). PMID: 24058931
High frequency of herpesvirus-specific clonotypes in the human T cell repertoire can remain stable over decades with minimal turnover.
M A Neller, J M Burrows, +2 authors, S R Burrows.
J Virol, 2012 Oct 19; 87(1). PMID: 23077319    Free PMC article.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Brian Kavanagh, Shaun O'Brien, +6 authors, Lawrence Fong.
Blood, 2008 Jun 05; 112(4). PMID: 18523152    Free PMC article.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Michael R Robinson, Chi-Chao Chan, +5 authors, Steven A Rosenberg.
J Immunother, 2004 Nov 10; 27(6). PMID: 15534492
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin Sanderson, Ronald Scotland, +9 authors, Jeffrey Weber.
J Clin Oncol, 2004 Dec 23; 23(4). PMID: 15613700
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Geoffrey Y Ku, Jianda Yuan, +7 authors, Jedd D Wolchok.
Cancer, 2010 Feb 10; 116(7). PMID: 20143434    Free PMC article.
Highly Cited.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Peter Attia, Giao Q Phan, +14 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087944    Free PMC article.
Highly Cited.
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
John M Kirkwood, Paul Lorigan, +7 authors, Cecile A Bulanhagui.
Clin Cancer Res, 2010 Jan 21; 16(3). PMID: 20086001
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Antoni Ribas, Douglas C Hanson, +6 authors, Jesus Gomez-Navarro.
Oncologist, 2007 Aug 04; 12(7). PMID: 17673618
Review.
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Ajay V Maker, Peter Attia, Steven A Rosenberg.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301685    Free PMC article.
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Jianda Yuan, Sacha Gnjatic, +17 authors, Jedd D Wolchok.
Proc Natl Acad Sci U S A, 2008 Dec 17; 105(51). PMID: 19074257    Free PMC article.
Highly Cited.
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
Begoña Comin-Anduix, Yohan Lee, +13 authors, Antoni Ribas.
J Transl Med, 2008 May 03; 6. PMID: 18452610    Free PMC article.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
Erika von Euw, Thinle Chodon, +4 authors, Antoni Ribas.
J Transl Med, 2009 May 22; 7. PMID: 19457253    Free PMC article.
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
Antoni Ribas, Matthias R Benz, +7 authors, Johannes Czernin.
J Nucl Med, 2010 Feb 13; 51(3). PMID: 20150263
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.
Lidia Robert, Christina Harview, +8 authors, Antoni Ribas.
Oncoimmunology, 2014 Aug 02; 3. PMID: 25083336    Free PMC article.
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.
David L Bajor, Xiaowei Xu, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2014 Sep 26; 2(11). PMID: 25252722    Free PMC article.
Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.
Helga Schneider, Christopher E Rudd.
Front Immunol, 2014 Dec 30; 5. PMID: 25538704    Free PMC article.
Review.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Kevin Van der Jeught, Lukasz Bialkowski, +7 authors, Karine Breckpot.
Oncotarget, 2015 Feb 16; 6(3). PMID: 25682197    Free PMC article.
Review.
Targeting cancer-specific mutations by T cell receptor gene therapy.
Thomas Blankenstein, Matthias Leisegang, Wolfgang Uckert, Hans Schreiber.
Curr Opin Immunol, 2015 Mar 03; 33. PMID: 25728991    Free PMC article.
Review.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, +22 authors, Andy J Minn.
Nature, 2015 Mar 11; 520(7547). PMID: 25754329    Free PMC article.
Highly Cited.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Review.
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.
Michael A Postow, Manuarii Manuel, +9 authors, Jedd D Wolchok.
J Immunother Cancer, 2015 Jun 19; 3. PMID: 26085931    Free PMC article.
Highly Cited.
Immune monitoring technology primer: immunosequencing.
Ilan Kirsch.
J Immunother Cancer, 2015 Jun 27; 3. PMID: 26113978    Free PMC article.
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Tomoe Higuchi, Dallas B Flies, +4 authors, Sarah F Adams.
Cancer Immunol Res, 2015 Jul 04; 3(11). PMID: 26138335    Free PMC article.
Highly Cited.
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Manami Miyai, Shingo Eikawa, +8 authors, Kazuhiro Kakimi.
PLoS One, 2015 Aug 21; 10(8). PMID: 26291626    Free PMC article.
T-cell receptor profiling in cancer.
Ilan Kirsch, Marissa Vignali, Harlan Robins.
Mol Oncol, 2015 Sep 26; 9(10). PMID: 26404496    Free PMC article.
Review.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Engineered Materials for Cancer Immunotherapy.
Alexander S Cheung, David J Mooney.
Nano Today, 2015 Dec 08; 10(4). PMID: 26640511    Free PMC article.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
Review.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
The urgent need to recover MHC class I in cancers for effective immunotherapy.
Federico Garrido, Natalia Aptsiauri, +2 authors, Thorbald van Hall.
Curr Opin Immunol, 2016 Jan 23; 39. PMID: 26796069    Free PMC article.
Highly Cited. Review.
Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.
Elizabeth Ernestina Godoy-Lozano, Juan Téllez-Sosa, +14 authors, Jesús Martínez-Barnetche.
Genome Med, 2016 Feb 27; 8(1). PMID: 26917418    Free PMC article.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
Review.
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination.
Melody Hsu, Shaina Sedighim, +13 authors, Robert M Prins.
Cancer Immunol Res, 2016 Mar 13; 4(5). PMID: 26968205    Free PMC article.
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Jon Bjoern, Nikolaj Juul Nitschke, +3 authors, Inge Marie Svane.
Oncoimmunology, 2016 May 04; 5(4). PMID: 27141381    Free PMC article.
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Seongseok Yun, Nicole D Vincelette, +2 authors, Ivo Abraham.
Cancer Med, 2016 May 12; 5(7). PMID: 27167347    Free PMC article.
Systematic Review.
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.
Jing Nie, Yan Zhang, +3 authors, Weidong Han.
Oncotarget, 2016 Oct 23; 7(25). PMID: 27191266    Free PMC article.
Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.
Jennifer S Sims, Boris Grinshpun, +7 authors, Jeffrey N Bruce.
Proc Natl Acad Sci U S A, 2016 Jun 05; 113(25). PMID: 27261081    Free PMC article.
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Aude G Chapuis, Ilana M Roberts, +12 authors, Cassian Yee.
J Clin Oncol, 2016 Jun 09; 34(31). PMID: 27269940    Free PMC article.
Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samples.
Joseph Kaplinsky, Ramy Arnaout.
Nat Commun, 2016 Jun 16; 7. PMID: 27302887    Free PMC article.
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
Michael D Iglesia, Joel S Parker, +3 authors, Benjamin G Vincent.
J Natl Cancer Inst, 2016 Jun 24; 108(11). PMID: 27335052    Free PMC article.
Highly Cited.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Seth P Lerner, Dean F Bajorin, +33 authors, Diane Zipursky Quale.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376138    Free PMC article.
Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Natalie Vandeven, Paul Nghiem.
Immunotherapy, 2016 Jul 07; 8(8). PMID: 27381685    Free PMC article.
Review.
High-content molecular profiling of T-cell therapy in oncology.
Ruslan Novosiadly, Michael Kalos.
Mol Ther Oncolytics, 2016 Sep 15; 3. PMID: 27626060    Free PMC article.
Review.
TCR diversity - a universal cancer immunotherapy biomarker?
Douglas G McNeel.
J Immunother Cancer, 2016 Nov 24; 4. PMID: 27879971    Free PMC article.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu-Lieskovan.
J Exp Med, 2016 Dec 03; 213(13). PMID: 27903604    Free PMC article.
Highly Cited. Review.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Review.
Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes.
Howard R Seay, Erik Yusko, +14 authors, Todd M Brusko.
JCI Insight, 2016 Dec 13; 1(20). PMID: 27942583    Free PMC article.
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.
Mack Y Su, David E Fisher.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959922    Free PMC article.
T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.
David Schrama, Cathrin Ritter, Jürgen C Becker.
Semin Immunopathol, 2017 Jan 12; 39(3). PMID: 28074285
Review.
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer.
Cell Commun Signal, 2017 Jan 20; 15(1). PMID: 28100240    Free PMC article.
Review.
Identifying T Cell Receptors from High-Throughput Sequencing: Dealing with Promiscuity in TCRα and TCRβ Pairing.
Edward S Lee, Paul G Thomas, Jeff E Mold, Andrew J Yates.
PLoS Comput Biol, 2017 Jan 20; 13(1). PMID: 28103239    Free PMC article.
Neutrophils dominate the immune cell composition in non-small cell lung cancer.
Julia Kargl, Stephanie E Busch, +8 authors, A McGarry Houghton.
Nat Commun, 2017 Feb 02; 8. PMID: 28146145    Free PMC article.
Highly Cited.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Review.
Applications of Immunogenomics to Cancer.
X Shirley Liu, Elaine R Mardis.
Cell, 2017 Feb 12; 168(4). PMID: 28187283    Free PMC article.
Highly Cited. Review.
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Jason Lohmueller, Olivera J Finn.
Pharmacol Ther, 2017 Mar 23; 178. PMID: 28322974    Free PMC article.
Review.
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, +13 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515944    Free PMC article.
Highly Cited. Review.
T cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3 sequences.
Asaf Madi, Asaf Poran, +10 authors, Nir Friedman.
Elife, 2017 Jul 22; 6. PMID: 28731407    Free PMC article.
Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.
M Bahador, A Gras Navarro, +8 authors, M Chekenya.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919997    Free PMC article.
Towards a better cancer precision medicine: systems biology meets immunotherapy.
Bhavneet Bhinder, Olivier Elemento.
Curr Opin Syst Biol, 2017 Oct 11; 2. PMID: 28989987    Free PMC article.
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Charissa A C Jessurun, Julien A M Vos, Jacqueline Limpens, Rosalie M Luiten.
Front Oncol, 2017 Oct 17; 7. PMID: 29034210    Free PMC article.
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.
Ingunn M Stromnes, Ayaka Hulbert, +2 authors, Sunil R Hingorani.
Cancer Immunol Res, 2017 Oct 27; 5(11). PMID: 29066497    Free PMC article.
Highly Cited.
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Nils-Petter Rudqvist, Karsten A Pilones, +7 authors, Sandra Demaria.
Cancer Immunol Res, 2017 Nov 29; 6(2). PMID: 29180535    Free PMC article.
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Zhuting Hu, Patrick A Ott, Catherine J Wu.
Nat Rev Immunol, 2017 Dec 12; 18(3). PMID: 29226910    Free PMC article.
Highly Cited. Review.
Regulatory T cells constrain the TCR repertoire of antigen-stimulated conventional CD4 T cells.
Martina Fontaine, Isabel Vogel, +6 authors, Oberdan Leo.
EMBO J, 2017 Dec 22; 37(3). PMID: 29263148    Free PMC article.
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.
Mirjana Efremova, Dietmar Rieder, +8 authors, Zlatko Trajanoski.
Nat Commun, 2018 Jan 04; 9(1). PMID: 29296022    Free PMC article.
Highly Cited.
Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Akihiro Hosoi, Kazuyoshi Takeda, +10 authors, Kazuhiro Kakimi.
Sci Rep, 2018 Jan 20; 8(1). PMID: 29348598    Free PMC article.
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.
Erika J Crosby, Junping Wei, +10 authors, Zachary C Hartman.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721371    Free PMC article.
Immune checkpoint inhibitors and radiotherapy-concept and review of current literature.
Loka Thangamathesvaran, Roshni Shah, Rebeka Verma, Omar Mahmoud.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862244    Free PMC article.
Review.
VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.
Scott Christley, Walter Scarborough, +14 authors, Lindsay G Cowell.
Front Immunol, 2018 Jun 06; 9. PMID: 29867956    Free PMC article.
Melanoma Immunotherapy: Next-Generation Biomarkers.
Sabrina A Hogan, Mitchell P Levesque, Phil F Cheng.
Front Oncol, 2018 Jun 14; 8. PMID: 29896449    Free PMC article.
Review.
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Janet Retseck, Alexis Nasr, +4 authors, Ahmad A Tarhini.
J Transl Med, 2018 Jul 06; 16(1). PMID: 29973204    Free PMC article.
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Alexander C Hopkins, Mark Yarchoan, +7 authors, Elizabeth M Jaffee.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997287    Free PMC article.
Highly Cited.
Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Keishi Adachi, Koji Tamada.
J Gastroenterol, 2018 Jul 14; 53(9). PMID: 30003334    Free PMC article.
Review.
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.
Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122997    Free PMC article.
Review.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
Review.
Biomarkers in melanoma: where are we now?
Douglas B Johnson, Ryan J Sullivan.
Melanoma Manag, 2014 Nov 01; 1(2). PMID: 30190819    Free PMC article.
Review.
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.
Wouter W van Willigen, Martine Bloemendal, +3 authors, Kalijn F Bol.
Front Immunol, 2018 Oct 18; 9. PMID: 30327656    Free PMC article.
Highly Cited. Review.
Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology.
Francesca Finotello, Federica Eduati.
Front Oncol, 2018 Oct 23; 8. PMID: 30345255    Free PMC article.
Review.
T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.
Benjamin A Kansy, Gulidanna Shayan, +8 authors, Robert L Ferris.
Oncoimmunology, 2018 Nov 01; 7(11). PMID: 30377562    Free PMC article.
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Wouter Ouwerkerk, Mirjam van den Berg, +2 authors, Rosalie M Luiten.
Melanoma Res, 2019 Mar 12; 29(5). PMID: 30855527    Free PMC article.
Systematic Review.
Current Perspectives in Cancer Immunotherapy.
Theodoulakis Christofi, Stavroula Baritaki, +2 authors, Apostolos Zaravinos.
Cancers (Basel), 2019 Oct 03; 11(10). PMID: 31575023    Free PMC article.
Review.
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Kroopa Joshi, Marc Robert de Massy, +32 authors, Benny Chain.
Nat Med, 2019 Oct 09; 25(10). PMID: 31591606    Free PMC article.
The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients.
Arjun Khunger, Julie A Rytlewski, +2 authors, Ahmad A Tarhini.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646098    Free PMC article.
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Andrew B Nixon, Kurt A Schalper, +3 authors, Catherine Fleener.
J Immunother Cancer, 2019 Nov 30; 7(1). PMID: 31775882    Free PMC article.
Review.
Cancer immune escape: MHC expression in primary tumours versus metastases.
Federico Garrido, Natalia Aptsiauri.
Immunology, 2019 Sep 12; 158(4). PMID: 31509607    Free PMC article.
Review.
Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Neil M Steven, Benjamin A Fisher.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816079    Free PMC article.
Review.
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Sophia C Weinmann, David S Pisetsky.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816080    Free PMC article.
Review.
From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions.
Manqing Wu, Jun Shen.
Front Oncol, 2019 Dec 12; 9. PMID: 31824865    Free PMC article.
Review.
Biomarker for personalized immunotherapy.
Si-Yang Liu, Yi-Long Wu.
Transl Lung Cancer Res, 2019 Dec 21; 8(Suppl 3). PMID: 31857954    Free PMC article.
Review.
The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
Kroopa Joshi, Benjamin M Chain, Karl S Peggs, Sergio A Quezada.
Cold Spring Harb Perspect Med, 2017 Jun 21; 8(1). PMID: 28630228    Free PMC article.
Review.
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Lindsey M Kuehm, Kyle Wolf, +2 authors, Ryan M Teague.
Cancer Immunol Immunother, 2019 May 20; 68(7). PMID: 31104075    Free PMC article.
Differential skewing of donor-unrestricted and γδ T cell repertoires in tuberculosis-infected human lungs.
Paul Ogongo, Adrie Jc Steyn, +5 authors, Samuel M Behar.
J Clin Invest, 2019 Nov 26; 130(1). PMID: 31763997    Free PMC article.
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Shaheen Khan, David E Gerber.
Semin Cancer Biol, 2019 Jul 23; 64. PMID: 31330185    Free PMC article.
Review.
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.
Sarah Whelan, Eran Ophir, +17 authors, Spencer C Liang.
Cancer Immunol Res, 2019 Jan 20; 7(2). PMID: 30659054    Free PMC article.
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Sara Valpione, Elena Galvani, +13 authors, Richard Marais.
Nat Cancer, 2020 Feb 29; 1(2). PMID: 32110781    Free PMC article.
Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Tara M Robinson, Gabrielle T Prince, +6 authors, B Douglas Smith.
Leuk Lymphoma, 2018 Apr 05; 59(12). PMID: 29616857    Free PMC article.
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.
Amer M Zeidan, Hanna A Knaus, +17 authors, B Douglas Smith.
Clin Cancer Res, 2018 May 03; 24(15). PMID: 29716921    Free PMC article.
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Thorben Mährle, Nuray Akyüz, +9 authors, Mascha Binder.
Haematologica, 2019 Jan 19; 104(7). PMID: 30655375    Free PMC article.
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
David Agdashian, Mei ElGindi, +13 authors, Firouzeh Korangy.
Cancer Immunol Immunother, 2019 Jan 29; 68(4). PMID: 30688989    Free PMC article.
TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration.
Hiroyasu Aoki, Satoshi Ueha, +5 authors, Kouji Matsushima.
Front Immunol, 2019 Feb 09; 9. PMID: 30733724    Free PMC article.
High throughput sequencing of T-cell receptor repertoire using dry blood spots.
Shang-Gin Wu, Wenjing Pan, +6 authors, Song Li.
J Transl Med, 2019 Feb 20; 17(1). PMID: 30777078    Free PMC article.
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay, Christophe Caux.
J Immunother Cancer, 2019 Mar 30; 7(1). PMID: 30922400    Free PMC article.
Highly Cited. Review.
Detecting T cell receptors involved in immune responses from single repertoire snapshots.
Mikhail V Pogorelyy, Anastasia A Minervina, +4 authors, Aleksandra M Walczak.
PLoS Biol, 2019 Jun 14; 17(6). PMID: 31194732    Free PMC article.
Clinical Applications of Next-Generation Sequencing in Precision Oncology.
Chris A Karlovich, P Mickey Williams.
Cancer J, 2019 Jul 25; 25(4). PMID: 31335390    Free PMC article.
CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.
Christina Friese, Katja Harbst, +7 authors, Özcan Met.
Sci Rep, 2020 Mar 05; 10(1). PMID: 32127601    Free PMC article.
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
Mausam Patel, Somaira Nowsheen, Sanjay Maraboyina, Fen Xia.
Cell Biosci, 2020 Mar 18; 10. PMID: 32180937    Free PMC article.
Review.
CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Josselyn E Garcia-Perez, Ryan M Baxter, +7 authors, Elena W Y Hsieh.
Front Immunol, 2019 Jun 04; 10. PMID: 31156616    Free PMC article.
Mechanisms of checkpoint inhibition-induced adverse events.
P Urwyler, I Earnshaw, +9 authors, S Papa.
Clin Exp Immunol, 2020 Jan 29; 200(2). PMID: 31989585    Free PMC article.
Review.
Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma.
Akiko Arakawa, Sigrid Vollmer, +5 authors, Jörg C Prinz.
Front Immunol, 2019 Jul 06; 10. PMID: 31275310    Free PMC article.
Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy.
Ilenia Aversa, Donatella Malanga, Giuseppe Fiume, Camillo Palmieri.
Int J Mol Sci, 2020 Apr 03; 21(7). PMID: 32235561    Free PMC article.
Review.
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.
Changqing Xie, Austin G Duffy, +21 authors, Tim F Greten.
Hepatology, 2018 Dec 24; 69(5). PMID: 30578687    Free PMC article.
RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy.
Ekaterina A Zhigalova, Anna I Izosimova, +7 authors, George V Sharonov.
Front Oncol, 2020 May 16; 10. PMID: 32411589    Free PMC article.
Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
Masato Saito, Toshihiko Ishii, +10 authors, Takashi Ishida.
Blood Adv, 2020 May 21; 4(10). PMID: 32433748    Free PMC article.
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Satya Das, Audrey Allen, Jordan Berlin.
Clin Colorectal Cancer, 2020 Mar 09; 19(2). PMID: 32146081    Free PMC article.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Review.
Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma.
Fei Wang, Xiaohong Xie, +14 authors, Chengzhi Zhou.
Ann Transl Med, 2020 Jul 11; 8(12). PMID: 32647675    Free PMC article.
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Takemasa Tsuji, Kevin H Eng, +13 authors, Kunle Odunsi.
Oncotarget, 2020 Jul 18; 11(27). PMID: 32676168    Free PMC article.
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.
Vanessa Acebes-Fernández, Alicia Landeria-Viñuela, +5 authors, Manuel Fuentes.
Nanomaterials (Basel), 2020 Jul 03; 10(7). PMID: 32610601    Free PMC article.
Review.
CD8+ T cell states in human cancer: insights from single-cell analysis.
Anne M van der Leun, Daniela S Thommen, Ton N Schumacher.
Nat Rev Cancer, 2020 Feb 07; 20(4). PMID: 32024970    Free PMC article.
Review.
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
S Klein, D Ghersi, +3 authors, A R M Kraft.
J Virol, 2020 Jul 10; 94(18). PMID: 32641478    Free PMC article.
Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model.
Xuan Ye, Janelle C Waite, +12 authors, Dimitris Skokos.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923116    Free PMC article.
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.
Boris Shulgin, Yuri Kosinsky, +8 authors, Gabriel Helmlinger.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934874    Free PMC article.
Review.
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy.
Michael Dougan.
Cancer Immunol Res, 2020 Oct 03; 8(10). PMID: 33004412    Free PMC article.
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade.
Weilei Hu, Guosheng Wang, +2 authors, Ming You.
iScience, 2020 Oct 22; 23(10). PMID: 33083746    Free PMC article.
Review.
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses.
Joel Kidman, Nicola Principe, +6 authors, Jonathan Chee.
Front Immunol, 2020 Nov 10; 11. PMID: 33163002    Free PMC article.
Review.
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
Edward F Fritsch, Ute E Burkhardt, Nir Hacohen, Catherine J Wu.
Cancer Immunol Res, 2020 Dec 03; 8(12). PMID: 33262163    Free PMC article.
Review.
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Alexey Berezhnoy, Bradley J Sumrow, +16 authors, Paul A Moore.
Cell Rep Med, 2020 Dec 31; 1(9). PMID: 33377134    Free PMC article.
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Anastasia Mpakali, Efstratios Stratikos.
Cancers (Basel), 2021 Jan 08; 13(1). PMID: 33406696    Free PMC article.
Review.
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
You Lu, Jianxin Xue, +35 authors, Tony Mok.
Nat Med, 2020 Apr 29; 26(5). PMID: 32341578
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups.
Sanghoon Lee, Li Zhao, +6 authors, Anil K Sood.
iScience, 2021 Feb 05; 24(2). PMID: 33537658    Free PMC article.
Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
S Ji, J Li, +11 authors, J Xu.
Clin Transl Oncol, 2021 Feb 15; 23(8). PMID: 33583004
De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection.
Daria Beshnova, Jianfeng Ye, +6 authors, Bo Li.
Sci Transl Med, 2020 Aug 21; 12(557). PMID: 32817363    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Review.
A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade.
Hagit Philip, Tom Snir, +3 authors, Sol Efroni.
iScience, 2021 Feb 20; 24(2). PMID: 33604527    Free PMC article.
Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
Shuo Zhang, Ziyue Zhou, +3 authors, Xiaofeng Zeng.
Ther Adv Chronic Dis, 2021 Feb 27; 12. PMID: 33633822    Free PMC article.
Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.
Vito Olschewski, Hanno M Witte, +8 authors, Niklas Gebauer.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33672644    Free PMC article.
Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy.
Li Qian, Zhang Zhaohui, +10 authors, Liang Li.
Thorac Cancer, 2021 Feb 25; 12(7). PMID: 33626215    Free PMC article.
Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
Beate Husain, Michael Constantin Kirchberger, +5 authors, Lucie Heinzerling.
J Cancer Res Clin Oncol, 2021 Apr 11; 147(6). PMID: 33837821    Free PMC article.
Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines.
Kue Peng Lim, Nur Syafinaz Zainal.
Front Mol Biosci, 2021 May 04; 8. PMID: 33937323    Free PMC article.
Review.
Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.
Xiaoli Wang, Guoliang Qiao, +11 authors, Herbert Kim Lyerly.
Am J Cancer Res, 2021 May 06; 11(4). PMID: 33948384    Free PMC article.
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
Yucai Wang, Sutapa Sinha, +15 authors, Wei Ding.
Blood Cancer J, 2021 May 12; 11(5). PMID: 33972504    Free PMC article.
The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors.
Tiffany C Blair, Alejandro F Alice, +2 authors, Michael J Gough.
Front Oncol, 2021 May 11; 11. PMID: 33968757    Free PMC article.
Review.
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Amber G Bozward, Frazer Warricker, Ye H Oo, Salim I Khakoo.
Front Immunol, 2021 May 18; 12. PMID: 33995362    Free PMC article.
Review.
Immune-related cutaneous adverse events due to checkpoint inhibitors.
Evelyn Wang, Lukas Kraehenbuehl, +3 authors, Donald Y M Leung.
Ann Allergy Asthma Immunol, 2021 Feb 21; 126(6). PMID: 33609771    Free PMC article.
Review.
Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity.
Jenna L Collier, Sarah A Weiss, +2 authors, Arlene H Sharpe.
Nat Immunol, 2021 Jun 19; 22(7). PMID: 34140679
Review.
Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy.
Anca Bobircă, Florin Bobircă, +6 authors, Anca Emanuela Mușetescu.
Biology (Basel), 2021 Jul 03; 10(6). PMID: 34203101    Free PMC article.
Review.
Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients.
Ning Dong, Andrea Moreno-Manuel, +9 authors, Eloísa Jantus-Lewintre.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34204662    Free PMC article.
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment.
Qin Xie, Jian Ding, Yi Chen.
Acta Pharm Sin B, 2021 Jul 06; 11(6). PMID: 34221857    Free PMC article.
Review.
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
Spyridoula Vasileiou, Premal D Lulla, +19 authors, George Carrum.
J Clin Oncol, 2021 Jan 29; 39(13). PMID: 33507803    Free PMC article.
Diversity and shared T-cell receptor repertoire analysis in esophageal squamous cell carcinoma.
Tomoya Sudo, Akihiko Kawahara, +12 authors, Yoshito Akagi.
Oncol Lett, 2021 Jul 15; 22(2). PMID: 34257726    Free PMC article.
Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non-Small-Cell Lung Cancer Patients Treated With the Anti-PD-L1 Antibody.
Jin Sheng, Huadi Wang, +11 authors, Yong Fang.
Front Mol Biosci, 2021 Jul 27; 8. PMID: 34307450    Free PMC article.
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.
Ryan J Sullivan, Jeffrey S Weber.
Nat Rev Drug Discov, 2021 Jul 29;. PMID: 34316029
Review.
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Alexander Stein, Donjete Simnica, +24 authors, Mascha Binder.
J Immunother Cancer, 2021 Jul 29; 9(7). PMID: 34315821    Free PMC article.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Livius Penter, Yi Zhang, +35 authors, Catherine J Wu.
Blood, 2021 Mar 16; 137(23). PMID: 33720354    Free PMC article.
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
David M Francis, Margaret P Manspeaker, +6 authors, Susan N Thomas.
Sci Transl Med, 2020 Oct 02; 12(563). PMID: 32998971    Free PMC article.
GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation.
Hongyi Zhang, Xiaowei Zhan, Bo Li.
Nat Commun, 2021 Aug 06; 12(1). PMID: 34349111    Free PMC article.
60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.
Nicoletta Cieri, Katie Maurer, Catherine J Wu.
Cancer Res, 2021 Jun 11; 81(17). PMID: 34108142    Free PMC article.
Review.
The methods and advances of adaptive immune receptors repertoire sequencing.
Hongmei Liu, Wenjing Pan, +6 authors, Song Li.
Theranostics, 2021 Sep 16; 11(18). PMID: 34522220    Free PMC article.
PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy.
Dominique Delmas, François Hermetet, Virginie Aires.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572736    Free PMC article.
Review.
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Hussein A Abbas, Dapeng Hao, +31 authors, Andrew Futreal.
Nat Commun, 2021 Oct 20; 12(1). PMID: 34663807    Free PMC article.
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.
Michael Burke, Sawsan Rashdan.
Front Oncol, 2021 Oct 19; 11. PMID: 34660286    Free PMC article.
Review.
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Cara Haymaker, Daniel H Johnson, +22 authors, Adi Diab.
Cancer Discov, 2021 Mar 13; 11(8). PMID: 33707233    Free PMC article.
Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels.
Jiamin Cheng, Yinyin Li, +10 authors, Zhen Zeng.
J Hepatocell Carcinoma, 2021 Nov 06; 8. PMID: 34737983    Free PMC article.
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Daniel Hirschhorn, Allison Betof Warner, +11 authors, Jedd D Wolchok.
JCI Insight, 2021 Oct 23; 6(20). PMID: 34676831    Free PMC article.
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor.
Åsa Kristina Öjlert, Daniel Nebdal, +5 authors, Åslaug Helland.
Mol Oncol, 2021 Aug 18; 15(11). PMID: 34402187    Free PMC article.
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma.
Pramod Savarapu, Basel Abdelazeem, +2 authors, Arvind Kunadi.
J Community Hosp Intern Med Perspect, 2021 Nov 23; 11(6). PMID: 34804411    Free PMC article.
Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy.
Antonella Cardinale, Carmen Dolores De Luca, Franco Locatelli, Enrico Velardi.
Front Immunol, 2021 Dec 14; 12. PMID: 34899700    Free PMC article.
Review.
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review.
Joosje C Baltussen, Marij J P Welters, +7 authors, Nienke A de Glas.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944986    Free PMC article.
Review.
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Elena Goleva, Taras Lyubchenko, +3 authors, Jeffrey A Kern.
Ann Allergy Asthma Immunol, 2021 Mar 16; 126(6). PMID: 33716146    Free PMC article.
Review.
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Alexander X Lozano, Aadel A Chaudhuri, +17 authors, Aaron M Newman.
Nat Med, 2022 Jan 15; 28(2). PMID: 35027754    Free PMC article.
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Hema Dave, Madeline Terpilowski, +14 authors, Catherine M Bollard.
Blood Adv, 2021 Sep 09; 6(2). PMID: 34495306    Free PMC article.
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Olivier Michielin, Aly-Khan Lalani, +2 authors, Solange Peters.
J Immunother Cancer, 2022 Jan 27; 10(1). PMID: 35078922    Free PMC article.
Review.
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Nanruoyi Zhou, Maria A Velez, +14 authors, Aaron Lisberg.
Lung Cancer, 2021 Sep 11; 161. PMID: 34507111    Free PMC article.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, +33 authors, Adil Daud.
Lancet Oncol, 2015 Jun 28; 16(8). PMID: 26115796    Free PMC article.
Highly Cited.
Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy.
Shadma Fatima, Yafeng Ma, +7 authors, Paul de Souza.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406441    Free PMC article.
Review.
Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
Andrea Aran, Laia Garrigós, +2 authors, Mercè Martí.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406543    Free PMC article.
Review.
Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.
Guanqun Yang, Ligang Xing, Xiaorong Sun.
Front Immunol, 2022 Apr 16; 13. PMID: 35422812    Free PMC article.
Review.
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.
Angelika M Starzer, Matthias Preusser, Anna S Berghoff.
Ther Adv Med Oncol, 2022 May 06; 14. PMID: 35510032    Free PMC article.
Review.
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.
Runzhe Chen, Jun Li, +20 authors, Alexandre Reuben.
J Exp Clin Cancer Res, 2022 May 14; 41(1). PMID: 35546239    Free PMC article.
TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC.
Yuntao Wang, Yi Liu, +6 authors, Yifeng Bai.
Front Pharmacol, 2022 May 24; 13. PMID: 35600862    Free PMC article.